RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Pronged attack on advanced head and neck cancer enters major trial
Disease control Recruiting nowThis study is testing a new drug called ficerafusp alfa, which is designed to attack cancer cells in two ways at once. It is being given alongside an existing immunotherapy drug (pembrolizumab) to people with advanced head and neck cancer that has returned or spread. The goal is …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
New combo therapy trial aims to extend lives in Tough-to-Treat cancer recurrence
Disease control Recruiting nowThis study is testing whether a two-step treatment—first repeat radiation with chemotherapy, followed by immunotherapy—works better than immunotherapy alone (with or without chemotherapy) for people whose head and neck cancer has returned locally. It will enroll about 214 adults …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New immune cell therapy combo aims to fight tough head & neck cancers
Disease control Recruiting nowThis study is testing whether a combination of three treatments—a modified immune cell infusion, an immune-stimulating protein, and an approved targeted antibody—is safe and effective for people with advanced head and neck cancer that has returned or spread. It is for patients wh…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo aims to supercharge immune system to fight cancer before surgery
Disease control Recruiting nowThis study is testing if adding a new immune-boosting drug (CDX-1140) to an existing immunotherapy (cemiplimab) works better before surgery for advanced head and neck cancer. The goal is to shrink the tumor more effectively, which could lead to less extensive surgery. About 44 pa…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Cholesterol drug may boost cancer treatment in new trial
Disease control Recruiting nowThis study is testing whether adding the common cholesterol-lowering drug lovastatin to the immunotherapy drug pembrolizumab can better control head and neck cancer that has returned or spread. Researchers believe lovastatin may make cancer cells more vulnerable to the immune sys…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for Tough-to-Treat head & neck cancer recurrence
Disease control Recruiting nowThis study is for people whose head and neck cancer has come back after initial treatment. After surgery, it compares a newer immunotherapy drug (pembrolizumab) to the standard combination of chemotherapy and radiation. The main goal is to see if the immunotherapy helps patients …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Light beam targets cancer in new head & neck treatment trial
Disease control Recruiting nowThis study is testing whether a new light-activated drug (ASP-1929) works better when combined with an immunotherapy drug (pembrolizumab) for people whose head and neck cancer has come back locally. It will compare this new combination to the current standard treatments. The main…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Doctors test custom vaccine to fight returning head and neck cancer
Disease control Recruiting nowThis early-stage study is testing a personalized vaccine made from a patient's own tumor cells. It aims to see if the vaccine, given alone or with an immunotherapy drug (pembrolizumab), is safe and can help the immune system fight advanced head and neck cancer that has returned o…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?
Disease control Recruiting nowThis study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard platinum-based chemotherapy. It aims to see if combining two immunotherapy drugs (pembrolizumab and cetuximab) helps patients live longer than using pemb…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
Cancer care comes home: mayo clinic tests At-Home immunotherapy shots
Disease control Recruiting nowThis study is testing whether giving a cancer immunotherapy treatment called nivolumab as an injection at home is a safe and practical alternative to receiving it at a clinic. It aims to see if home treatment reduces the burden of travel and improves quality of life for patients …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New hope for patients when standard immunotherapy stops working
Disease control Recruiting nowThis study is testing if a drug called cetuximab can help control head and neck cancer that has returned or spread after standard immunotherapy has stopped working. It will involve about 38 adults who have already tried a PD-1 inhibitor drug. The main goal is to see if the cancer…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Radioactive tracer aims to pinpoint hidden cancer in lymph nodes
Diagnosis Recruiting nowThis early-stage study is testing a new radioactive imaging drug to see if it can safely and accurately find the first lymph nodes where head and neck cancer has spread. The test involves injecting the drug before surgery and using a special scan to create a map for surgeons. The…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Mar 23, 2026 15:14 UTC
-
Glowing dye trial aims to light up hidden cancer cells during surgery
Diagnosis Recruiting nowThis early-stage study is testing the safety of two new imaging dyes designed to help surgeons see head and neck cancer cells more clearly. The dyes are injected before surgery and make cancer cells glow or show up on special scans, potentially helping surgeons remove more of the…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Mar 19, 2026 14:55 UTC
-
New blood test could reveal Cancer's next move
Knowledge-focused Recruiting nowThis study aims to learn if a new type of blood test can predict how recurrent or metastatic head and neck cancer will progress. Researchers will analyze blood samples from 30 patients to look for specific cancer cells and immune cells. The goal is to see if these findings can he…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC